{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:41:02Z","timestamp":1794109262874,"version":"4.8.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT-28-18"],"award-info":[{"award-number":["SU2C-AACR-DT-28-18"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT-28-18"],"award-info":[{"award-number":["SU2C-AACR-DT-28-18"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Myeloma Society Career Development Award"},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41588-025-02196-0","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:03:03Z","timestamp":1747803783000},"page":"1493-1503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Genomic landscape of multiple myeloma and its precursor conditions"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7294","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Alberge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit K.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0753-1248","authenticated-orcid":false,"given":"Andrea","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5826-3554","authenticated-orcid":false,"given":"Tim H. H.","family":"Coorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Lightbody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Toenges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4999-2605","authenticated-orcid":false,"given":"Xavi","family":"Loinaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dunford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody J.","family":"Boehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nang K.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadley","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hevenor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Towle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmika","family":"Beesam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna B.","family":"Beckwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-8338","authenticated-orcid":false,"given":"David M.","family":"Cordas dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-9011","authenticated-orcid":false,"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-5579","authenticated-orcid":false,"given":"Kirsten","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-9836","authenticated-orcid":false,"given":"Peter F.","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Terragna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-6360","authenticated-orcid":false,"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-6254","authenticated-orcid":false,"given":"Brian A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1387-4009","authenticated-orcid":false,"given":"Julian","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chip","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"2196_CR1","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362\u20131369 (2006).","journal-title":"N. Engl. J. Med."},{"key":"2196_CR2","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2196_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle, R. A. et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 378, 241\u2013249 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2196_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).","journal-title":"Blood Cancer J."},{"key":"2196_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"M-V Mateos","year":"2020","unstructured":"Mateos, M.-V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).","journal-title":"Blood Cancer J."},{"key":"2196_CR6","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan, A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 10, e203\u2013e212 (2023).","journal-title":"Lancet Haematol."},{"key":"2196_CR7","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-24-0210","volume":"30","author":"D Kazandjian","year":"2024","unstructured":"Kazandjian, D. et al. Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma. Clin. Cancer Res. 30, 4482\u20134490 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2196_CR8","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros, M. et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J. Clin. Oncol. 38, 2380\u20132390 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2196_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20524-2","volume":"12","author":"EM Boyle","year":"2021","unstructured":"Boyle, E. M. et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat. Commun. 12, 293 (2021).","journal-title":"Nat. Commun."},{"key":"2196_CR10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura, F. et al. Genomic classification and individualized prognosis in multiple myeloma. J. Clin. Oncol. 42, 1229\u20131240 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2196_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00980-5","volume":"14","author":"NH Abdallah","year":"2024","unstructured":"Abdallah, N. H. et al. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 14, 9 (2024).","journal-title":"Blood Cancer J."},{"key":"2196_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker, B. A. et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28, 384\u2013390 (2014).","journal-title":"Leukemia"},{"key":"2196_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).","journal-title":"Nat. Commun."},{"key":"2196_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","volume":"102","author":"A Mikulasova","year":"2017","unstructured":"Mikulasova, A. et al. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102, 1617\u20131625 (2017).","journal-title":"Haematologica"},{"key":"2196_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli, N. et al. Genomic patterns of progression in smoldering multiple myeloma. Nat. Commun. 9, 3363 (2018).","journal-title":"Nat. Commun."},{"key":"2196_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta, A. K. et al. Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability. Leukemia 33, 457\u2013468 (2019).","journal-title":"Leukemia"},{"key":"2196_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura, F. et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 10, 3835 (2019).","journal-title":"Nat. Commun."},{"key":"2196_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","volume":"13","author":"AK Dutta","year":"2023","unstructured":"Dutta, A. K. et al. MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology. Cancer Discov. 13, 348\u2013363 (2023).","journal-title":"Cancer Discov."},{"key":"2196_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41596-020-00437-6","volume":"16","author":"P Ellis","year":"2021","unstructured":"Ellis, P. et al. Reliable detection of somatic mutations in solid tissues by laser-capture microdissection and low-input DNA sequencing. Nat. Protoc. 16, 841\u2013871 (2021).","journal-title":"Nat. Protoc."},{"key":"2196_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"2196_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1084\/jem.20031571","volume":"199","author":"M Cortes","year":"2004","unstructured":"Cortes, M. & Georgopoulos, K. Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity. J. Exp. Med. 199, 209\u2013219 (2004).","journal-title":"J. Exp. Med."},{"key":"2196_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ccell.2021.02.003","volume":"39","author":"G Lazarian","year":"2021","unstructured":"Lazarian, G. et al. A hotspot mutation in transcription factor IKZF3 drives B\u2009cell neoplasia via transcriptional dysregulation. Cancer Cell 39, 380\u2013393.e8 (2021).","journal-title":"Cancer Cell"},{"key":"2196_CR23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B. et al. Molecular subtypes of diffuse large B\u2009cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690 (2018).","journal-title":"Nat. Med."},{"key":"2196_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100\u2013113 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2196_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15740-9","volume":"11","author":"EH Rustad","year":"2020","unstructured":"Rustad, E. H. et al. Timing the initiation of multiple myeloma. Nat. Commun. 11, 1917 (2020).","journal-title":"Nat. Commun."},{"key":"2196_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G., Gupta, V. A., Vertino, P. M. & Boise, L. H. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front. Immunol. 10, 1121 (2019).","journal-title":"Front. Immunol."},{"key":"2196_CR27","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","volume":"121","author":"BA Walker","year":"2013","unstructured":"Walker, B. A. et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121, 3413\u20133419 (2013).","journal-title":"Blood"},{"key":"2196_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2196_CR29","doi-asserted-by":"publisher","unstructured":"K\u00fcbler, K. et al. Tumor mutational landscape is a record of the pre-malignant state. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/517565 (2019).","DOI":"10.1101\/517565"},{"key":"2196_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41586-022-05072-7","volume":"608","author":"HE Machado","year":"2022","unstructured":"Machado, H. E. et al. Diverse mutational landscapes in human lymphocytes. Nature 608, 724\u2013732 (2022).","journal-title":"Nature"},{"key":"2196_CR31","first-page":"1623","volume":"17","author":"Y Teh","year":"2004","unstructured":"Teh, Y., Jordan, M., Beal, M. & Blei, D. Sharing clusters among related groups: hierarchical Dirichlet processes. Adv. Neural Inf. Process. Syst. 17, 1623\u20131634 (2004).","journal-title":"Adv. Neural Inf. Process. Syst."},{"key":"2196_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"2196_CR33","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).","journal-title":"Nat. Commun."},{"key":"2196_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9866","volume":"6","author":"S Kasar","year":"2015","unstructured":"Kasar, S. et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866 (2015).","journal-title":"Nat. Commun."},{"key":"2196_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau, D. A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525\u2013530 (2015).","journal-title":"Nature"},{"key":"2196_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970\u2013976 (2013).","journal-title":"Nat. Genet."},{"key":"2196_CR37","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","volume":"34","author":"K Misund","year":"2020","unstructured":"Misund, K. et al. MYC dysregulation in the progression of multiple myeloma. Leukemia 34, 322\u2013326 (2020).","journal-title":"Leukemia"},{"key":"2196_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22140-0","volume":"12","author":"B Oben","year":"2021","unstructured":"Oben, B. et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat. Commun. 12, 1861 (2021).","journal-title":"Nat. Commun."},{"key":"2196_CR39","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41587-022-01353-8","volume":"40","author":"MA Sherman","year":"2022","unstructured":"Sherman, M. A. et al. Genome-wide mapping of somatic mutation rates uncovers drivers of cancer. Nat. Biotechnol. 40, 1634\u20131643 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2196_CR40","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget, S. et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat. Genet. 56, 1878\u20131889 (2024).","journal-title":"Nat. Genet."},{"key":"2196_CR41","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien, J. et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat. Cancer 4, 1536\u20131543 (2023).","journal-title":"Nat. Cancer"},{"key":"2196_CR42","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee, H. et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat. Med. 29, 2295\u20132306 (2023).","journal-title":"Nat. Med."},{"key":"2196_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier, S. et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat. Commun. 9, 1691 (2018).","journal-title":"Nat. Commun."},{"key":"2196_CR44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","volume":"19","author":"Y Mishima","year":"2017","unstructured":"Mishima, Y. et al. The mutational landscape of circulating tumor cells in multiple myeloma. Cell Rep. 19, 218\u2013224 (2017).","journal-title":"Cell Rep."},{"key":"2196_CR45","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1038\/s41375-020-0883-0","volume":"34","author":"J-J Garc\u00e9s","year":"2020","unstructured":"Garc\u00e9s, J.-J. et al. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia 34, 3007\u20133018 (2020).","journal-title":"Leukemia"},{"key":"2196_CR46","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41375-018-0115-z","volume":"32","author":"G Guo","year":"2018","unstructured":"Guo, G. et al. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia 32, 1838\u20131841 (2018).","journal-title":"Leukemia"},{"key":"2196_CR47","doi-asserted-by":"publisher","first-page":"363ra147","DOI":"10.1126\/scitranslmed.aac7037","volume":"8","author":"JG Lohr","year":"2016","unstructured":"Lohr, J. G. et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci. Transl. Med. 8, 363ra147 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2196_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/ejh.13541","volume":"106","author":"S Deshpande","year":"2021","unstructured":"Deshpande, S. et al. Monitoring treatment response and disease progression in myeloma with circulating cell\u2010free DNA. Eur. J. Haematol. 106, 230\u2013240 (2021).","journal-title":"Eur. J. Haematol."},{"key":"2196_CR49","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41375-021-01492-y","volume":"36","author":"JM Waldschmidt","year":"2022","unstructured":"Waldschmidt, J. M. et al. Cell-free DNA for the detection of emerging treatment failure in relapsed\/refractory multiple myeloma. Leukemia 36, 1078\u20131087 (2022).","journal-title":"Leukemia"},{"key":"2196_CR50","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","volume":"54","author":"BA Knisbacher","year":"2022","unstructured":"Knisbacher, B. A. et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat. Genet. 54, 1664\u20131674 (2022).","journal-title":"Nat. Genet."},{"key":"2196_CR51","doi-asserted-by":"publisher","unstructured":"Leshchiner, I. et al. Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/508127 (2019).","DOI":"10.1101\/508127"},{"key":"2196_CR52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","volume":"602","author":"N Williams","year":"2022","unstructured":"Williams, N. et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature 602, 162\u2013168 (2022).","journal-title":"Nature"},{"key":"2196_CR53","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.3324\/haematol.2023.283191","volume":"108","author":"A\u00dd Sigurbergsd\u00f3ttir","year":"2023","unstructured":"Sigurbergsd\u00f3ttir, A. \u00dd. et al. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study. Haematologica 108, 3392 (2023).","journal-title":"Haematologica"},{"key":"2196_CR54","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"2196_CR55","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos, D. M. et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat. Med. 30, 2667\u20132678 (2024).","journal-title":"Nat. Med."},{"key":"2196_CR56","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-024-07328-w","volume":"629","author":"V Parreno","year":"2024","unstructured":"Parreno, V. et al. Transient loss of Polycomb components induces an epigenetic cancer fate. Nature 629, 688\u2013696 (2024).","journal-title":"Nature"},{"key":"2196_CR57","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","volume":"24","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos, D. M., Toenges, R., Bertamini, L., Alberge, J.-B. & Ghobrial, I. M. New horizons in our understanding of precursor multiple myeloma and early interception. Nat. Rev. Cancer 24, 867\u2013886 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2196_CR58","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage, E. J. et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N. Engl. J. Med. 384, 924\u2013935 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2196_CR59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"2196_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2196_CR61","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Inform."},{"key":"2196_CR62","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","journal-title":"J. Biomed. Inform."},{"key":"2196_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55308-5","volume":"16","author":"O Nadeem","year":"2025","unstructured":"Nadeem, O. et al. Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial. Nat. Commun. 16, 358 (2025).","journal-title":"Nat. Commun."},{"key":"2196_CR64","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https:\/\/arxiv.org\/abs\/1303.3997 (2013)."},{"key":"2196_CR65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"2196_CR66","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"2196_CR67","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gks1443","volume":"41","author":"M Costello","year":"2013","unstructured":"Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).","journal-title":"Nucleic Acids Res."},{"key":"2196_CR68","first-page":"656","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent, W. J. BLAT\u2014the BLAST-like alignment tool. Genome Res. 12, 656\u2013664 (2002).","journal-title":"Genome Res."},{"key":"2196_CR69","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41592-018-0036-9","volume":"15","author":"A Taylor-Weiner","year":"2018","unstructured":"Taylor-Weiner, A. et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods 15, 531\u2013534 (2018).","journal-title":"Nat. Methods"},{"key":"2196_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17453-5","volume":"11","author":"N Javed","year":"2020","unstructured":"Javed, N. et al. Detecting sample swaps in diverse NGS data types using linkage disequilibrium. Nat. Commun. 11, 3697 (2020).","journal-title":"Nat. Commun."},{"key":"2196_CR71","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/bioinformatics\/btr446","volume":"27","author":"K Cibulskis","year":"2011","unstructured":"Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601\u20132602 (2011).","journal-title":"Bioinformatics"},{"key":"2196_CR72","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","volume":"3","author":"K Wienand","year":"2019","unstructured":"Wienand, K. et al. Genomic analyses of flow-sorted Hodgkin Reed\u2013Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 3, 4065\u20134080 (2019).","journal-title":"Blood Adv."},{"key":"2196_CR73","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s43018-023-00533-y","volume":"4","author":"I Leshchiner","year":"2023","unstructured":"Leshchiner, I. et al. Inferring early genetic progression in cancers with unobtainable premalignant disease. Nat. Cancer 4, 550\u2013563 (2023).","journal-title":"Nat. Cancer"},{"key":"2196_CR74","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2016).","journal-title":"Bioinformatics"},{"key":"2196_CR75","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1101\/gr.221028.117","volume":"28","author":"JA Wala","year":"2018","unstructured":"Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581\u2013591 (2018).","journal-title":"Genome Res."},{"key":"2196_CR76","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1101\/gr.141382.112","volume":"23","author":"Y Drier","year":"2013","unstructured":"Drier, Y. et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 23, 228\u2013235 (2013).","journal-title":"Genome Res."},{"key":"2196_CR77","doi-asserted-by":"publisher","first-page":"eabg2538","DOI":"10.1126\/science.abg2538","volume":"372","author":"LM Morton","year":"2021","unstructured":"Morton, L. M. et al. Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science 372, eabg2538 (2021).","journal-title":"Science"},{"key":"2196_CR78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"2196_CR79","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"2196_CR80","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41586-020-1965-x","volume":"578","author":"E Rheinbay","year":"2020","unstructured":"Rheinbay, E. et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature 578, 102\u2013111 (2020).","journal-title":"Nature"},{"key":"2196_CR81","doi-asserted-by":"publisher","unstructured":"Loinaz, X. et al. SVelfie: a method for discovering cancer drivers based on enrichment of likely functional structural variants. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.03.09.642284 (2025).","DOI":"10.1101\/2025.03.09.642284"},{"key":"2196_CR82","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41586-021-03822-7","volume":"597","author":"L Moore","year":"2021","unstructured":"Moore, L. et al. The mutational landscape of human somatic and germline cells. Nature 597, 381\u2013386 (2021).","journal-title":"Nature"},{"key":"2196_CR83","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","volume":"578","author":"M Gerstung","year":"2020","unstructured":"Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122\u2013128 (2020).","journal-title":"Nature"},{"key":"2196_CR84","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMoa2000962","volume":"383","author":"TH Coorens","year":"2020","unstructured":"Coorens, T. H. et al. Lineage-independent tumors in bilateral neuroblastoma. N. Engl. J. Med. 383, 1860\u20131865 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2196_CR85","first-page":"324","volume":"39","author":"RA Bradley","year":"1952","unstructured":"Bradley, R. A. & Terry, M. E. Rank analysis of incomplete block designs: I. The method of paired comparisons. Biometrika 39, 324\u2013345 (1952).","journal-title":"Biometrika"},{"key":"2196_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i09","volume":"48","author":"H Turner","year":"2012","unstructured":"Turner, H. & Firth, D. Bradley\u2013Terry models in R: the BradleyTerry2 package. J. Stat. Softw. 48, 1\u201321 (2012).","journal-title":"J. Stat. Softw."},{"key":"2196_CR87","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-20-2245","volume":"27","author":"F Maura","year":"2021","unstructured":"Maura, F. et al. Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001. Clin. Cancer Res. 27, 2111\u20132118 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2196_CR88","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. B"},{"key":"2196_CR89","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-020-2493-4","volume":"583","author":"F Abascal","year":"2020","unstructured":"Abascal, F. et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature 583, 699\u2013710 (2020).","journal-title":"Nature"},{"key":"2196_CR90","doi-asserted-by":"publisher","unstructured":"Alberge, J. B. jalberge\/ms-wgs (v0.9.0). Zenodo https:\/\/doi.org\/10.5281\/zenodo.14774594 (2025).","DOI":"10.5281\/zenodo.14774594"},{"key":"2196_CR91","doi-asserted-by":"publisher","unstructured":"Poletti, A. andrea-poletti-unibo\/MS_TiMMing: TiMMing (clonality League Model). Zenodo https:\/\/doi.org\/10.5281\/zenodo.14813516 (2025).","DOI":"10.5281\/zenodo.14813516"},{"key":"2196_CR92","doi-asserted-by":"publisher","unstructured":"Loinaz, X. getzlab\/SVelfie: SVelfie v0.0.1. Zenodo https:\/\/doi.org\/10.5281\/zenodo.15132973 (2025).","DOI":"10.5281\/zenodo.15132973"},{"key":"2196_CR93","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/blood-2024-205523","volume":"144","author":"J-B Alberge","year":"2024","unstructured":"Alberge, J.-B. et al. Novel non-coding candidate drivers of multiple myeloma linked to plasma cell tumor biology and B\u2009cell development. Blood 144, 1894 (2024).","journal-title":"Blood"},{"key":"2196_CR94","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1182\/blood-2024-203517","volume":"144","author":"J-B Alberge","year":"2024","unstructured":"Alberge, J.-B. et al. A 1,000-genome map for multiple myeloma and its precursor stages, and its impact on clinical outcome. Blood 144, 1019 (2024).","journal-title":"Blood"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02196-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02196-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02196-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:02:31Z","timestamp":1749819751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02196-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2196"],"URL":"https:\/\/doi.org\/10.1038\/s41588-025-02196-0","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.-B.A., A.K.D., G.G. and I.M.G. are inventors on patent applications for MinimuMM-seq and for the MM-like score. A.K.D. and E.D.L. have consulted for and received honoraria from Menarini Silicon Biosystems. G.G. receives research funds from IBM, Pharmacyclics\/Abbvie, Bayer, Genentech, Calico, Ultima Genomics, Inocras, Google, Kite and Novartis, and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye, MinimuMM-seq, and DLBclass. He is a founder, consultant and holds private equity in Scorpion Therapeutics; he is also a founder of and holds privately held equity in Predicta Biosciences. He was also a consultant to Merck. I.M.G. has consulted for Bristol-Myers Squibb, AstraZeneca, Amgen, Curio Science, Sanofi, Janssen, Pfizer, Menarini Silicone Biosystems, Aptitude Health, GlaxoSmithKline, AbbVie, Adaptive Biotechnologies, Window Therapeutics and Regeneron. She has received honoraria or speaker fees from Vor Biopharma, Janssen, MJH Life Sciences, Novartis, Takeda, Amgen, Regeneron, Curio Science, Standard Biotools and Physicians\u2019 Education Resource. She is a founder and executive board member of and holds private equity in Predicta Biosciences. Her spouse is the chief medical officer of and holds private equity in Disc Medicine. R.S.P. is a founder, consultant and holds equity in Predicta Biosciences. E.Z. has received honoraria and served in advisory roles for Janssen, Bristol-Myers Squibb, Sanofi, Amgen, GlaxoSmithKline, Pfizer, Oncopeptides and Menarini\u2013Stemline. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}